Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NIVOTHYM
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
- NCT03134118 ↗
- Active, not recruiting
- European Organisation for Research and Treatment of Cancer - EORTC
- Standard
We haven't built an HCP commentary report on NIVOTHYM (nivolumab in previously treated type B3 thymoma and thymic carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NIVOTHYM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Thymoma Type B3; Thymic Carcinoma
- Interventions
- Nivolumab
- Arms
- Nivolumab · Experimental
- Enrollment
- 55 (estimated)
- Primary outcomes
- Progression Free Survival Rate (PFSR) at month 6
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC with ETOP IBCSG Partners Foundation
- Start
- Apr 11, 2018
- Primary completion
- Sep 5, 2023
- Results posted
- No
- Registry record
- NCT03134118 · updated May 15, 2026
Publications
linked from the registry- Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. PubMed 34393061